Delcath Systems, Inc. (DCTH)
After hours: 05:11PM EDT
- GlobeNewswire
Delcath Systems to Present at Upcoming Virtual Investor Conferences
NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences: H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021 Presentation Date and Time: On-demand beginning 9/13/2021 at 7:00 AM (ET)Webcast: https://journey.ct.events/view/ee8971f7-2bcf-428c-91e5-3ff7d70376abManage
- GlobeNewswire
Delcath Systems Announces Second Quarter 2021 Results
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021. Recent Business Highlights During and since the second quarter the company: Had positive efficacy results presented from its FOCUS Phase III trial of HEPZATO™ KIT (melphalan hydrochloride for injection/he
- GlobeNewswire
Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional details concerning the debt facility will be contained in the company's Current Report on Form
